Written by
Mustafa Çelik
Mustafa Çelik Liv Hospital Content Team
Medically reviewed by

Related Doctors

Assoc. Prof. MD. Evrim Duman Liv Hospital Ulus Assoc. Prof. MD. Evrim Duman Radiation Oncology Asst. Prof. MD. Meltem Topalgökçeli Selam Liv Hospital Ulus Asst. Prof. MD. Meltem Topalgökçeli Selam Medical Oncology Prof. MD. Duygu Derin Liv Hospital Ulus Prof. MD. Duygu Derin Medical Oncology Prof. MD. Emre Merdan Fayda Liv Hospital Ulus Prof. MD. Emre Merdan Fayda Radiation Oncology Prof. MD. Meral Günaldı Liv Hospital Ulus Prof. MD. Meral Günaldı Medical Oncology Assoc. Prof. MD. Murat Ayhan Liv Hospital Vadistanbul Assoc. Prof. MD. Murat Ayhan Medical Oncology Prof. MD.  Itır Şirinoğlu Demiriz Liv Hospital Vadistanbul Prof. MD. Itır Şirinoğlu Demiriz Hematology Prof. MD. Tülin Tıraje Celkan Liv Hospital Vadistanbul Prof. MD. Tülin Tıraje Celkan Pediatric Hematology and Oncology Assoc. Prof. MD. Erkan Kayıkçıoğlu Liv Hospital Bahçeşehir Assoc. Prof. MD. Erkan Kayıkçıoğlu Medical Oncology Assoc. Prof. MD. Mine Dağgez Liv Hospital Bahçeşehir Assoc. Prof. MD. Mine Dağgez Gynecological Oncology Assoc. Prof. MD. Ozan Balakan Liv Hospital Bahçeşehir Assoc. Prof. MD. Ozan Balakan Medical Oncology MD. Taylan Bükülmez Liv Hospital Bahçeşehir MD. Taylan Bükülmez Radiation Oncology Op. MD. Alp Koray Kinter Liv Hospital Bahçeşehir Op. MD. Alp Koray Kinter Gynecological Oncology Prof. MD. Nuri Faruk Aykan Liv Hospital Bahçeşehir Prof. MD. Nuri Faruk Aykan Medical Oncology Prof. MD. Yasemin Altuner Torun Liv Hospital Bahçeşehir Prof. MD. Yasemin Altuner Torun Pediatric Hematology and Oncology Spec. MD. Özlem Doğan Liv Hospital Bahçeşehir Spec. MD. Özlem Doğan Medical Oncology Assoc. Prof. MD. Emir Çelik Liv Hospital Topkapı Assoc. Prof. MD. Emir Çelik Medical Oncology Assoc. Prof. MD. Muhammed Mustafa Atcı Liv Hospital Topkapı Assoc. Prof. MD. Muhammed Mustafa Atcı Medical Oncology Prof. MD. İrfan Çiçin Liv Hospital Topkapı Prof. MD. İrfan Çiçin Medical Oncology Assoc. Prof. MD.  Ramazan Öcal Liv Hospital Ankara Assoc. Prof. MD. Ramazan Öcal Hematology Assoc. Prof. MD. Nazlı Topfedaisi Özkan Liv Hospital Ankara Assoc. Prof. MD. Nazlı Topfedaisi Özkan Gynecological Oncology Prof. MD. Fikret Arpacı Liv Hospital Ankara Prof. MD. Fikret Arpacı Medical Oncology Prof. MD. Gökhan Erdem Liv Hospital Ankara Prof. MD. Gökhan Erdem Medical Oncology Prof. MD. Meral Beksaç Liv Hospital Ankara Prof. MD. Meral Beksaç Hematology Prof. MD. Oral Nevruz Liv Hospital Ankara Prof. MD. Oral Nevruz Hematology Prof. MD. Saadettin Kılıçkap Liv Hospital Ankara Prof. MD. Saadettin Kılıçkap Medical Oncology Prof. MD. Sadık Muallaoğlu Liv Hospital Ankara Prof. MD. Sadık Muallaoğlu Medical Oncology Spec. MD. Ender Kalacı Liv Hospital Ankara Spec. MD. Ender Kalacı Medical Oncology Assoc. Prof. MD. Fadime Ersoy Dursun Liv Hospital Gaziantep Assoc. Prof. MD. Fadime Ersoy Dursun Hematology Prof. MD. Fatih Teker Liv Hospital Gaziantep Prof. MD. Fatih Teker Medical Oncology Spec. MD. ELXAN MEMMEDOV Liv Bona Dea Hospital Bakü Spec. MD. ELXAN MEMMEDOV Medical Oncology Spec. MD. Ceyda Aslan Spec. MD. Ceyda Aslan Hematology Spec. MD. Elkhan Mammadov Spec. MD. Elkhan Mammadov Medical Oncology Spec. MD. Elmir İsrafilov Spec. MD. Elmir İsrafilov Hematology Spec. MD. Minure Abışova Eliyeva Spec. MD. Minure Abışova Eliyeva Hematology Spec. MD. Natavan Azizova Spec. MD. Natavan Azizova Medical Oncology Prof. MD. Mehmet Hilmi Doğu Liv Hospital Ulus + Liv Hospital Bahçeşehir Prof. MD. Mehmet Hilmi Doğu Hematology
...
Views
Read Time
...
views
Read Time

Drug Overview

Prostate cancer relies on certain hormones in the body to grow and spread. Abiraterone acetate is a highly effective, modern medicine designed to cut off the fuel supply that these cancer cells need. It is classified as a powerful Targeted Therapy.

Here is a quick overview of the drug’s essential profile:

  • Generic Name: abiraterone acetate
  • US Brand Names: Zytiga, Yonsa
  • Drug Class: Androgen Biosynthesis Inhibitor / Antineoplastic (Anti-cancer) Agent
  • Route of Administration: Oral (Taken by mouth as a tablet)
  • FDA Approval Status: Fully FDA-approved for specific stages of advanced prostate cancer.

What Is It and How Does It Work? (Mechanism of Action)

Abiraterone Acetate
Abiraterone Acetate 2

To understand how abiraterone acetate works, we must look at how prostate cancer cells get their energy. Prostate cancer cells use male hormones called androgens (like testosterone) as “fuel” to grow and multiply.

Even if a patient has treatments to stop the testicles from making testosterone, the body’s adrenal glands and the prostate tumors themselves can still make small amounts of this fuel. Abiraterone acetate acts as a Targeted Therapy to stop this hidden production.

Here is how it works at the molecular level:

  1. The Target: Deep inside the body’s cells, there is a specific enzyme (a worker protein) called CYP17A1. This enzyme acts like a key assembly line machine that manufactures testosterone.
  2. The Blockade: When you take abiraterone acetate, the medicine finds and completely blocks the CYP17A1 enzyme in the testicles, the adrenal glands, and directly inside the tumor cells.
  3. Starving the Cancer: Because the assembly line is shut down, the body stops making androgens completely. Without this hormonal fuel, the prostate cancer cells stop growing, shrink, and eventually die.

Note: Because blocking this enzyme also stops the body from making other important, healthy hormones (like cortisol), patients must always take a steroid pill (like prednisone) alongside abiraterone acetate to keep the body in balance.

FDA Approved Clinical Indications

Oncological (Cancer-Related) uses:

  • Metastatic Castration-Resistant Prostate Cancer (mCRPC): For advanced prostate cancer that has spread to other parts of the body and no longer responds to standard hormone-lowering treatments.
  • Metastatic High-Risk Castration-Sensitive Prostate Cancer (mCSPC): For newly diagnosed, advanced prostate cancer that has spread but still responds to hormone therapy.

Non-oncological uses:

  • None. This medication is strictly used for hormone-driven cancers.

Dosage and Administration Protocols

Because there are two different brand-name versions of abiraterone acetate (Zytiga and Yonsa), they are absorbed by the body differently and have different rules for how to take them.

ParameterStandard Protocol
Standard Dose (Zytiga)1,000 mg once daily (usually two 500 mg tablets). Must be taken with 5 mg of prednisone twice daily.
Standard Dose (Yonsa)500 mg once daily (usually four 125 mg tablets). Must be taken with 4 mg of methylprednisolone twice daily.
Frequency / RouteTaken once a day, orally.
Food Instructions (Crucial)Zytiga: Must be taken on an completely empty stomach (no food for at least 2 hours before, and 1 hour after taking). Yonsa: Can be taken with or without food.
Hepatic (Liver) AdjustmentsThe dose must be lowered for patients with mild to moderate liver problems. It should not be used in patients with severe liver disease.

Clinical Efficacy and Research Results

Recent clinical data (2020-2025) confirms that abiraterone acetate remains a cornerstone treatment for advanced prostate cancer, greatly extending patients’ lives.

  • Survival Rates: In major, long-term clinical trials, adding abiraterone acetate to standard hormone therapy reduced the risk of death by approximately 30% to 38% compared to using standard therapy alone.
  • Disease Progression: The medication significantly delays the time it takes for the cancer to grow or spread to the bones. In many men, it adds years to their progression-free survival time.
  • Pain Reduction: Because it shrinks bone tumors effectively, patients often report a major decrease in cancer-related bone pain, leading to a much better quality of life during treatment.

Safety Profile and Side Effects

Because abiraterone acetate changes how your body makes hormones, it can cause specific side effects. Taking your daily steroid pill (prednisone) exactly as prescribed is the best way to prevent the most serious side effects.

Common side effects (>10%)

  • Feeling very tired (fatigue).
  • Joint swelling or muscle discomfort.
  • Hot flashes.
  • Fluid retention (swelling in the legs or feet).
  • High blood pressure (hypertension).

Serious adverse events

  • Liver Toxicity (Hepatotoxicity): The drug can cause severe liver damage. Regular blood tests are mandatory to check liver health.
  • Low Potassium (Hypokalemia): A drop in blood potassium levels, which can cause severe muscle weakness or heart rhythm problems.
  • Heart Problems: Worsening of heart failure or irregular heartbeats, often triggered by high blood pressure or low potassium.

Note: Abiraterone acetate does not have an FDA Black Box Warning, but strict warnings exist regarding liver damage and heart risks.

Management Strategies

If you notice sudden weight gain, severe swelling in your legs, or feel your heart racing, tell your doctor right away. Your healthcare team will regularly test your blood to catch low potassium or liver issues early. If your liver enzymes rise, your doctor may pause the medication until your liver heals, and then restart it at a lower dose.

Research Areas

While abiraterone acetate is already a highly successful Targeted Therapy, scientists are currently researching how to combine it with other cutting-edge treatments. Modern clinical trials are testing abiraterone acetate alongside PARP inhibitors (drugs that stop cancer cells from repairing their own DNA) and advanced Immunotherapy agents. Researchers hope that by starving the tumor with abiraterone acetate while simultaneously boosting the body’s immune system, they can create a deeper, longer-lasting response against the hardest-to-treat prostate cancers.

Patient Management and Practical Recommendations

Taking this medication requires strict attention to your daily routine to keep the drug levels safe and effective in your body.

Pre-treatment tests to be performed

  • Comprehensive liver function tests (ALT, AST, and bilirubin).
  • Heart health check (blood pressure check and possibly an ECG).
  • Complete blood count and a metabolic panel to check baseline potassium levels.

Precautions during treatment

  • You will need blood work every 2 weeks for the first three months, and then every month after that, to ensure your liver is handling the drug well.
  • Monitor your blood pressure at home regularly.

“Do’s and Don’ts” list

  • DO take your pills at the exact same time every day.
  • DO take your prescribed steroid (prednisone) exactly as directed. Never stop taking it suddenly, or you could become very sick.
  • DO tell your doctor if you have a history of heart disease, high blood pressure, or liver problems.
  • DON’T take Zytiga with food. Taking Zytiga with food can cause the body to absorb up to 10 times more of the drug than normal, which can cause a dangerous overdose. (Remember, Yonsa can be taken with food, so always check which brand you have).
  • DON’T crush or chew the tablets. Swallow them whole with water.
  • DON’T let women who are pregnant or may become pregnant touch the bare tablets, as the medicine can harm an unborn baby.

Legal Disclaimer

The information provided in this guide is for educational and informational purposes only and does not constitute medical advice. Abiraterone acetate is a prescription medication, and its safety and efficacy depend on proper usage under the guidance of a physician. Always consult with a qualified oncologist or healthcare provider regarding diagnosis, treatment options, and managing side effects tailored to your specific medical condition.

i

Medical Disclaimer

The content on this page is for informational purposes only and is not a substitute for professional medical advice, diagnosis or treatment. Always consult a qualified healthcare provider regarding any medical conditions.

Book a Free Certified Online
Doctor Consultation

Clinics/branches
GDPR

We're Here to Help.
Get in Touch

Send us all your questions or requests, and our
expert team will assist you.

Our Doctors

Assoc. Prof. MD. Evrim Duman Radiation Oncology

Assoc. Prof. MD. Evrim Duman

Liv Hospital Ulus
Asst. Prof. MD. Meltem Topalgökçeli Selam Medical Oncology

Asst. Prof. MD. Meltem Topalgökçeli Selam

Liv Hospital Ulus
Prof. MD. Duygu Derin Medical Oncology

Prof. MD. Duygu Derin

Liv Hospital Ulus
Prof. MD. Emre Merdan Fayda Radiation Oncology

Prof. MD. Emre Merdan Fayda

Liv Hospital Ulus
Prof. MD. Mehmet Hilmi Doğu Hematology

Prof. MD. Mehmet Hilmi Doğu

Liv Hospital Ulus
Liv Hospital Bahçeşehir
Prof. MD. Meral Günaldı Medical Oncology

Prof. MD. Meral Günaldı

Liv Hospital Ulus
Assoc. Prof. MD. Murat Ayhan Medical Oncology

Assoc. Prof. MD. Murat Ayhan

Liv Hospital Vadistanbul
Prof. MD.  Itır Şirinoğlu Demiriz Hematology

Prof. MD. Itır Şirinoğlu Demiriz

Liv Hospital Vadistanbul
Prof. MD. Tülin Tıraje Celkan Pediatric Hematology and Oncology

Prof. MD. Tülin Tıraje Celkan

Liv Hospital Vadistanbul
Assoc. Prof. MD. Erkan Kayıkçıoğlu Medical Oncology

Assoc. Prof. MD. Erkan Kayıkçıoğlu

Liv Hospital Bahçeşehir
Assoc. Prof. MD. Mine Dağgez Gynecological Oncology

Assoc. Prof. MD. Mine Dağgez

Liv Hospital Bahçeşehir
Assoc. Prof. MD. Ozan Balakan Medical Oncology

Assoc. Prof. MD. Ozan Balakan

Liv Hospital Bahçeşehir
MD. Taylan Bükülmez Radiation Oncology

MD. Taylan Bükülmez

Liv Hospital Bahçeşehir
Op. MD. Alp Koray Kinter Gynecological Oncology

Op. MD. Alp Koray Kinter

Liv Hospital Bahçeşehir
Prof. MD. Nuri Faruk Aykan Medical Oncology

Prof. MD. Nuri Faruk Aykan

Liv Hospital Bahçeşehir
Prof. MD. Yasemin Altuner Torun Pediatric Hematology and Oncology

Prof. MD. Yasemin Altuner Torun

Liv Hospital Bahçeşehir
Spec. MD. Özlem Doğan Medical Oncology

Spec. MD. Özlem Doğan

Liv Hospital Bahçeşehir
Assoc. Prof. MD. Emir Çelik Medical Oncology

Assoc. Prof. MD. Emir Çelik

Liv Hospital Topkapı
Assoc. Prof. MD. Muhammed Mustafa Atcı Medical Oncology

Assoc. Prof. MD. Muhammed Mustafa Atcı

Liv Hospital Topkapı
Prof. MD. İrfan Çiçin Medical Oncology

Prof. MD. İrfan Çiçin

Liv Hospital Topkapı
Assoc. Prof. MD.  Ramazan Öcal Hematology

Assoc. Prof. MD. Ramazan Öcal

Liv Hospital Ankara
Assoc. Prof. MD. Nazlı Topfedaisi Özkan Gynecological Oncology

Assoc. Prof. MD. Nazlı Topfedaisi Özkan

Liv Hospital Ankara
Prof. MD. Fikret Arpacı Medical Oncology

Prof. MD. Fikret Arpacı

Liv Hospital Ankara
Prof. MD. Gökhan Erdem Medical Oncology

Prof. MD. Gökhan Erdem

Liv Hospital Ankara
Prof. MD. Meral Beksaç Hematology

Prof. MD. Meral Beksaç

Liv Hospital Ankara
Prof. MD. Oral Nevruz Hematology

Prof. MD. Oral Nevruz

Liv Hospital Ankara
Prof. MD. Saadettin Kılıçkap Medical Oncology

Prof. MD. Saadettin Kılıçkap

Liv Hospital Ankara
Prof. MD. Sadık Muallaoğlu Medical Oncology

Prof. MD. Sadık Muallaoğlu

Liv Hospital Ankara
Spec. MD. Ender Kalacı Medical Oncology

Spec. MD. Ender Kalacı

Liv Hospital Ankara
Assoc. Prof. MD. Fadime Ersoy Dursun Hematology

Assoc. Prof. MD. Fadime Ersoy Dursun

Liv Hospital Gaziantep
Prof. MD. Fatih Teker Medical Oncology

Prof. MD. Fatih Teker

Liv Hospital Gaziantep
Spec. MD. ELXAN MEMMEDOV Medical Oncology

Spec. MD. ELXAN MEMMEDOV

Liv Bona Dea Hospital Bakü
Spec. MD. Ceyda Aslan Hematology

Spec. MD. Ceyda Aslan

Spec. MD. Elkhan Mammadov Medical Oncology

Spec. MD. Elkhan Mammadov

Spec. MD. Elmir İsrafilov Hematology

Spec. MD. Elmir İsrafilov

Spec. MD. Minure Abışova Eliyeva Hematology

Spec. MD. Minure Abışova Eliyeva

Spec. MD. Natavan Azizova Medical Oncology

Spec. MD. Natavan Azizova

Need Help? Chat with our medical team

Let's Talk on WhatsApp

📌

Get instant answers from our medical team. No forms, no waiting — just tap below to start chatting now.

or call us at +90 530 510 67 91